08-21-2017 01:55 PM CET - IT, New Media & Software
Print

Global HIV Drug Survey and Value Increase in Industry by 2023

Press release from: Big-Research

Big Market Research added a report on “HIV Drug Market By Medication Class (Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FI), Entry Inhibitors, And HIV Integrase Stand Transfer Inhibitors) - Global Opportunity Analysis And Industry Forecast, 2014-2022”

Human Immunodeficiency Virus (Hiv) Attacks The Body’s Immune System, Making The Host System Susceptible To Infection, And Thus Leading To Complete Damage. The Virus Attacks The Cd4 Cells, Which Help The Immune System Defend Infections. The Major Route Of Transmission Of Hiv Infection Is Through Unprotected Sex, Use Of Contaminated Needle, Breast Milk Of The Hiv Infected Mother, And Infected Blood.

The Global Hiv Drugs Market Was Valued At $20,448 Million In 2015, And Is Estimated To Reach $26,458 Million By 2022, Growing At A Cagr Of 3.7% During The Forecast Period From 2016 To 2022. The Major Factors That Boost The Growth Of The Market Include Increase In Prevalence Of Hiv Globally And Rise In Treatment & Diagnosis Rate. Moreover, Growth In Awareness About The Treatment Options & Care With The Various Initiatives And Education Campaigns Introduced By Government Agencies Across The Globe Plays An Important Role In The Growth Of Hiv Drugs Market. However, Stringent Government Regulations For The Approval And Commercialization Of Hiv Drugs Is Expected To Restrain The Growth Of The Hiv Drugs Market.

Request for Sample Copy@ www.bigmarketresearch.com/request-sample/1051326

The Report Segments The Market Based On Medication Class And Geography. On The Basis Of Medication Class, The Market Is Divided Into Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (Nrtis), Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), Protease Inhibitors (Pis), Fusion Inhibitors (Fi), Entry Inhibitors, Hiv Integrase Stand Transfer Inhibitors. Based On Geography, The Market Is Analyzed Across North America, Europe, Asia-Pacific, And Lamea. The North American Region Accounted For Around Half Of The Share In The Overall Hiv Drug Market In 2015, And Is Expected To Maintain This Lead Throughout The Forecast Period. The Growth In The Hiv Drug Market In The Region Is Attributed To Well-Established Healthcare System, Higher Diagnosis & Treatment Rate In The Region, And Development And Increase In The Adoption Of Advanced Treatment Options From The Hiv Infected Population.

For Purchase Enquiry@ www.bigmarketresearch.com/purchase-enquiry/1051326

KEY BENEFITS FOR STAKEHOLDERS
The Study Provides An In-Depth Analysis Of The Hiv Drugs Market, With Current Trends And Future Estimations To Elucidate The Imminent Investment Pockets.
It Presents A Quantitative Analysis From 2014 To 2022 To Enable The Stakeholders To Capitalize On Prevailing Market Opportunities.
Extensive Analysis Of The Hiv Drug Market, By Medication Class, Assists In The Effective Treatment Of Hiv/Aids.
Key Players Are Profiled And Their Strategies Are Analyzed Thoroughly, Which Predicts The Competitive Outlook Of The Market.

KEY MARKET SEGMENTATION
By Medication Class
• Multi-Class Combination Drugs
o Atripla
o Complera
o Prezcobix/Prezista
o Stribild
o Triumeq
• Nucleoside Reverse Transcriptase Inhibitors (Nrtis)
o Combivir
o Emtriva
o Epivir
o Epzicom
o Trizivir
o Truvada
o Viread
• Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)
o Edurant
o Intelence
o Rescriptor
o Sustiva
o Viramune (Immediate Release)
• Protease Inhibitors (Pis)
o Aptivus
o Crixivan
o Kaletra
o Lexiva
o Norvir
o Reyataz
o Viracept
• Fusion Inhibitors(Fi)
o Fuzeon
• Entry Inhibitors
o Selzentry
• Hiv Integrase Stand Transfer Inhibitors
o Isentress
o Tivicay

BY GEOGRAPHY
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Russia
o Czech Republic
o Poland
• Asia-Pacific
o China
o Australia
o India
o Indonesia

Key Players
• Boehringer Ingelheim International Gmbh
• Merck & Co.
• Bristol-Myers Squibb
• Gilead Sciences Inc.
• Viiv Healthcare
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Abbvie
• Cipla Limited

With the arsenal of different search reports, we help you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency. With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly. Our research services ranges into different domains and penetrates in different verticals so that we can carter to diverse needs of various organization. Not wrong to quote that this is the hotspot for research needs of yours. Big Market Research uniqueness lies in its highly ethical reports at economical rates because we value your relationship and growth more than money. Your growth is our aim.

Contact Us:
5933 NE Win Sivers Drive,
#205, Portland, OR 97220, United States
Direct: + 1-503-894-6022
Toll Free: + 1-800-910-6452
Email: help@bigmarketresearch.com
Web: www.bigmarketresearch.com

This release was published on openPR.
News-ID: 677444 • Views: 155
More releasesMore releases

You can edit or delete your press release here: